Biopharma Credit Share Price (BPCR)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -0.005 -0.5% 1.00 1,037,674 16:35:00
Bid Price Offer Price High Price Low Price Open Price
1.00 1.005 1.005 0.998 1.005
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown 142.34 113.82 8.28 12.1 1,374
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:00 UT 3 1.00 USD

Biopharma Credit (BPCR) Latest News (1)

Biopharma Credit News

Date Time Source Headline
22/1/202116:00UKREGBioPharma Credit PLC Net Asset Value(s) and Monthly Factsheet
31/12/202012:00UKREGBioPharma Credit PLC Director/PDMR Shareholding
21/12/202016:00UKREGBioPharma Credit PLC Net Asset Value(s) and Monthly Factsheet
20/11/202016:00UKREGBioPharma Credit PLC Net Asset Value(s) and Monthly Factsheet
12/11/202007:00UKREGBioPharma Credit PLC Dividend Declaration
09/11/202015:33ALNCIN BRIEF: BioPharma Credit To Invest Further USD75 Million In Epizyme
09/11/202007:00UKREGBioPharma Credit PLC ADDITIONAL INVESTMENT IN EPIZYME
21/10/202015:00UKREGBioPharma Credit PLC Net Asset Value(s) and Monthly Factsheet
13/10/202014:30UKREGBioPharma Credit PLC Holding(s) in Company
08/10/202013:00UKREGBioPharma Credit PLC Holding(s) in Company
More Biopharma Credit News
Biopharma Credit Investors    Biopharma Credit Takeover Rumours

Biopharma Credit (BPCR) Discussions and Chat

Biopharma Credit Forums and Chat

Date Time Title Posts
22/12/202011:43::: BIOPHARMA CREDIT PLC :::45

Add a New Thread

Biopharma Credit (BPCR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-22 16:35:001.0033.00UT
2021-01-22 16:29:421.0111.01AT
2021-01-22 16:27:581.01371372.86AT
2021-01-22 16:26:581.01192192.96AT
2021-01-22 16:26:461.00100,000100,000.00O
View all Biopharma Credit trades in real-time

Biopharma Credit (BPCR) Top Chat Posts

DateSubject
22/1/2021
08:20		Biopharma Credit Daily Update: Biopharma Credit Plc is listed in the Unknown sector of the London Stock Exchange with ticker BPCR. The last closing price for Biopharma Credit was US$1.01.
Biopharma Credit Plc has a 4 week average price of US$0.99 and a 12 week average price of US$0.97.
The 1 year high share price is US$1.03 while the 1 year low share price is currently US$0.85.
There are currently 1,373,872,373 shares in issue and the average daily traded volume is 898,504 shares. The market capitalisation of Biopharma Credit Plc is £1,373,872,373.
Read Full Thread
Reply
21/12/2020
21:16		speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/83953848 As at the 30 November 2020 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.91 cents. The Company's factsheet and investor presentation will be located on the Company's website, hxxp://bpcruk.com.
Read Full Thread
Follow
Reply
12/11/2020
11:42		speedsgh: Dividend Declaration - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/dividend-declaration/202011120700060560F/ BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 30 September 2020 of $0.0175 per ordinary share and a small special dividend in respect of the financial period ending 31 December 2019 of $0.0001 per ordinary share, payable on 18 December 2020 to ordinary shareholders on the register as at 20 November 2020. The Company has a small revenue reserve remaining for the fiscal year 2019 that it is distributing to ordinary shareholders. The Company has chosen to designate the entire amount of this interim and special dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company. The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.
Read Full Thread
Follow
Reply
09/11/2020
08:21		speedsgh: ADDITIONAL INVESTMENT IN EPIZYME - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/additional-investment-in-epizyme/202011090700115786E/ BioPharma Credit PLC (the "Company"), is pleased to announce that it, through its fully owned subsidiary, together with BioPharma Credit Investments V (Master) LP ("BioPharma-V" and jointly with the Company the "Lenders",) has entered into an amended and restated loan agreement with Epizyme, Inc ("Epizyme") dated 3 November 2020. As part of this amendment, the Company will invest an additional US$75 million in the Epizyme loan. Under the original terms of the loan agreement, executed in November 2019, Epizyme borrowed US$70 million in three tranches and the Company previously invested US$35 million with BioPharma-V investing the US$35 million balance. The original US$70 million loan will mature in November 2024 and bears interest at LIBOR plus 7.75 per cent. per annum along with a one-time additional consideration of 2.00 per cent. of the total loan amount. In addition, the facility was expandable by up to US$300 million, subject to mutual agreement between the Lenders and Epizyme after approval of tazemetostat for the treatment of follicular lymphoma. On 23 January 2020, TAZVERIK® was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with epithelioid sarcoma and on 18 June 2020 TAZVERIK received accelerated approval from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma. The amendment increases the aggregate principal amount of the loan to Epizyme to US$220 million through a US$150 million fourth tranche ("Tranche D"), which the parties expect to be drawn in full on 18 November 2020. The Company will invest US$75 million of the US$150 million Tranche D and BioPharma-V will invest the US$75 million balance. Tranche D will have the same fees and coupon as the earlier tranches, will be secured by the same collateral as the earlier tranches, and will mature in November 2026 after eight equal amortization payments beginning in February 2025. As part of the amendment, the amortization terms of the initial US$70 million advanced in the first three tranches were changed from eight equal quarterly payments starting in February 2023 to four equal quarterly payments starting in February 2024. Following the expected Tranche D closing, the facility will remain expandable by up to an additional US$150 million, subject to mutual agreement between the Lenders and Epizyme. "We are delighted to expand our partnership with Epizyme", said Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP. "TAZVERIK is now approved to meet the well-defined unmet patient needs in two very different indications (a solid tumor and a hematologic malignancy), demonstrating its broad therapeutic potential." Further to the 4 November 2019 announcement of the original loan agreement, Royalty Pharma continues to hold approximately 9.1% of the issued share capital of Epizyme and Pablo Legorreta, a principal of Pharmakon and Royalty Pharma, continues to be a member of Epizyme's board of directors.
Read Full Thread
Follow
Reply
21/10/2020
17:39		speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS://data.fca.org.uk/artefacts/NSM/RNS/3755523.html As at the 30 September 2020 the unaudited net asset value per Ordinary Share, including current period revenue, was 101.00 cents. The Company's factsheet will be located on the Company's website, HTTP://bpcruk.com.
Read Full Thread
Follow
Reply
02/10/2020
14:37		speedsgh: Director buys... On 30/9 Rolf Soderstrom (Director) bought 50,000 shares at £0.787344 = £39,367 HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/director-pdmr-shareholding/202010011100018035A/ On 30/9 Linda Davey (PCA to Rolf Soderstrom, Director of BioPharma Credit PLC) bought 50,000 shares at £0.787344 = £39,367 HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/director-pdmr-shareholding/202010011100018034A/
Read Full Thread
Follow
Reply
28/9/2020
15:06		speedsgh: STATEMENT REGARDING SAREPTA THERAPEUTICS - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/statement-regarding-sarepta-therapeutics/202009280700052023A/ BioPharma Credit PLC (the "Company"), is pleased to announce that, together with Sarepta Therapeutics, Inc ("Sarepta"), and BioPharma Credit Investments V (Master) LP ("BioPharma-V") it has entered into a first amendment to the loan agreement dated 13 December 2019. Under the original terms of the loan agreement, the Company agreed to invest up to US$350 million (US$175 million in the first tranche ("Tranche A") and up to an additional US$175 million by 31 December 2020 ("Tranche B")) and BioPharma-V agreed to invest up to US$150 million in parallel with the Company acting as collateral agent. The loan had an original maturity date of December 2023 and paid interest at 8.50 per cent. per annum along with a one-time additional consideration of 1.75 per cent. of the total loan amount payable upon funding and an additional 2.00 per cent. payable upon the repayment of the loan. The amendment increases the aggregate principal amount of Tranche B from US$250 million to US$300 million. The Company's investment in Tranche B will remain unchanged at US$175 million while BioPharma-V will increase its investment by US$50 million. The Company's US$350 million aggregate investment in Sarepta will represent 25% of the Company's portfolio. Sarepta has agreed to draw Tranche B in full, on or prior to 2 November 2020, as long as the conditions to funding the Tranche B are satisfied or waived. In addition, the Amendment extends the maturity date for the Tranche B Loan to 31 December 2024 and increases the funding fee payable to each Lender providing a portion of the Tranche B Loan on the date the Tranche B Loan is funded by 1.20 per cent. to 2.95 per cent.
Read Full Thread
Follow
Reply
16/9/2020
13:22		speedsgh: Half-year Report - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/half-year-report/202009160700050954Z/ Pedro Gonzalez de Cosio, CEO and co-founder of Pharmakon Advisors L. P., the Investment Manager of BioPharma Credit PLC, said: "During the first six months of 2020, Covid-19 has brought exceptional challenges to the global economy resulting in volatile conditions for many sectors and a significant reduction in global dividends. However, as a result of the Company's uncorrelated revenue stream, dividend payments have continued uninterrupted towards the ongoing annual target of 7 cents per share, just above a 7% dividend yield to our investors on the 30 June share price. It is the Company's objective to continue to offer a highly attractive long-term source of income uncorrelated to other markets. "The Company's investment activity in deploying specialised debt investments such as senior secured loans backed by important life science products has continued as normal with one significant new investment in Collegium Pharmaceuticals during the period and additional follow-on commitments in addition to some attractive pre-payments post-period end. "The environment continues to be attractive for the Company's investment strategy given the considerable and growing capital needs of the sector. This will be potentially enhanced by an anticipated increase in sector M&A activity and a slowdown in equity issuance that has tended historically to lead to a greater appetite for fixed income as a source of capital for the life sciences industry."
Read Full Thread
Follow
Reply
29/5/2020
03:02		rambutan2: More good news. The hefty Invesco overhang is gone: https://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Holdings-in-Company/82554964 I found this relevantly interesting: hTtps://capitalallocatorspodcast.com/2020/05/31/healthcare-royalty-partners/
Read Full Thread
Follow
Reply
26/5/2020
20:11		rambutan2: As predicted, and a good thing imho: NEW CREDIT FACILITY BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to announce that it has entered into a US$200 million credit facility (the "Credit Facility") with JPMorgan Chase Bank. The Credit Facility comprises a three-year US$200 million Revolving Credit Facility ("RCF"). The Company will pay a commitment fee on undrawn amounts of 200 basis points and a LIBOR margin of 400 basis points on drawn amounts. All borrowings under the Credit Facility are subject to compliance with certain covenants and the Company has provided charges over its subsidiaries' assets, including a charge over its subsidiaries' cash account and a floating charge over all of its subsidiaries' assets. As disclosed in the Company's latest Investor Update, as at 31 March 2020 the Company had a net cash position of US$64.3 million, or 5 per cent. of the Company's net asset value. Should the Revolving Credit Facility be fully drawn, aggregate borrowings would represent approximately 13 per cent. of the Company's net asset value. According to its Articles of Association, the Company may incur indebtedness of up to a maximum of 50 per cent. of its net asset value, calculated at the time of drawdown, for investment and for working capital purposes. Pharmakon Advisors, LP, the Company's Investment Manager, has agreed not to incur aggregate borrowings greater than 25 per cent. of the Company's net asset value, calculated at the time of drawdown, without prior Board approval. This facility provides for aggregate borrowings of less than 15 per cent. Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP, said "We are proud to partner with JPMorgan in the Company's inaugural credit facility. This new capital, together with expected cash flows from the portfolio, will provide greater flexibility in relation to new lending opportunities and provide complete coverage for downstream funding obligations."
Read Full Thread
Follow
Reply
12/2/2020
13:51		jonwig: WilliamC - NAV at 102c is higher than the share price. They won't try new equity until they can reverse that. I think ram was suggesting debt.
Read Full Thread
Follow
Reply
Biopharma Credit share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
BPCR
Biopharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210123 01:43:03